Anti-glomerular Basement Membrane Disease - Treatment Standard by Drs. Stephen McAdoo, Charles Pusey et al. academic.oup.com/ndt/article/do…

Atypical Hemotytic Uremic Syndrome (aHUS) - Prof. Fadi Fakhouri (Lausanne, Switzerland) youtu.be/k0UlfUh_PZU?si… Prof. Fakhouri discusses pathophysiology, diagnosis, treatment and prognosis of atypical Hemolytic Uremic Syndrome (aHUS).

Abnormal electrocardiogram findings in athletes by Drs. Gherardo Finocchiaro, Flavio D'Ascenzi et al. A consensus statement of the European Association of Preventive Cardiology of the European Society of Cardiology! academic.oup.com/eurheartj/arti…

Impfungen 25 / 26: Influenza, SARS-CoV-2, RSV, Pneumokokken - Prof. Dr. Klaus Stöhr, Prof. Dr. Barbara Gärtner Klaus Stöhr youtu.be/V5P-eDvf9jI?si…

Transthyretin amyloid cardiomyopathy: from cause to novel treatments by Drs. marianna fontana, Gillmore et al. academic.oup.com/eurheartj/arti…

The relationship between obesity and chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference by Drs. Furth, Peter Rossing et al. kidney-international.org/article/S0085-…

SGLT-2 Inhibition in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller youtu.be/9e-UFBnIyDI?si… Emilie Cornec-Le Gall Roman-Ulrich Müller Andreas Kronbichler Sara Helena Ksiazek Gunnar Henrik Heine Marcus Saemann

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes by Drs. Will Herrington, Natalie Staplin et al. sciencedirect.com/science/articl… SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.

Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial by Drs. Li, Li et al. academic.oup.com/eurheartj/arti… BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80.

Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK) youtu.be/kK8N-5RkEfc?si… Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus by Drs. Ronald van Vollenhov, Zhang et al. nejm.org/doi/full/10.10… The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.

Our experts explain: CKD of unexplained cause: ERA G & K Consensus - Prof. Emilie Cornec-Le Gall , Prof. Halbritter, Prof. Roman-Ulrich Müller youtu.be/RzupTGtHs8g?si… They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.

Urinary tract infection and continuation of SGLT-I in diabetic patients by Drs. Wu, Yiu et al. academic.oup.com/eurheartj/arti… Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.

Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury The BICARICU-2 Randomized Clinical Trial by Drs. boris jung, Samir JABER et al. jamanetwork.com/journals/jama/… In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.

Stream it now! Our webinar in cooperation with NDT: IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan Jonathan Barratt Jai Radhakrishnan NDT Andreas Kronbichler Gunnar Henrik Heine Hans-Joachim Anders youtu.be/l0g9_lkW5_w?si…

Short-Term Anticoagulation versus DAPT for Preventing Device Thrombosis Following LAAC: The ANDES RCT by Drs. Rodés-Cabau, Salaun et al. ahajournals.org/doi/10.1161/CI… The use of DOAC after LAAC failed to reduce DRT compared to DAPT but it was associated with an improved safety profile.

Rituximab for Relapsing Nephrotic Syndrome in Adults by Drs. Isaka, Hiromura et al. jamanetwork.com/journals/jama/… The relapse-free rate at week 49 was 87.4%(95% CI, 69.8%-95.1%) in the rituximab group and 38.0%(95% CI, 22.1%-53.8%) in the placebo group.

ESC Dyslipidemia Guidelines - 2025 Update - Prof. Dr. François Mach, Geneva, Switzerland youtu.be/-y_ma-kW61o?si… Prof. Mach presents the 2025 Focused Update of the European Guidelines for the management of dyslipidaemias, which have been published by European Society of Cardiology European Atherosclerosis Society .

What an exciting weekend... So many new studies to discuss!

A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: LIBERATE-D by Drs. Liu, Hsu et al. jamanetwork.com/journals/jama/… A conservative dialysis strategy promoted recovery from dialysis-requiring acute kidney injury.